← All trials
NCT04231266
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2020
- Primary completion
- Jan 31, 2023
- Completion date
- Jan 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 51
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Human Genome Research Institute (NHGRI)Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Collaborator
- National Human Genome Research Institute (NHGRI)Collaborator
- National Human Genome Research Institute (NHGRI)Sponsor investigator
- National Human Genome Research Institute (NHGRI)Overall official - principal investigator
- Leadiant Biosciences, Inc.Collaborator
- Harvard UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.